SILK Stock Cash Flow Statements

Silk Road Medical Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Silk Road Medical Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31

cash flows from operating activities
net income	-16,603,000	-14,136,000	-13,011,000	-12,788,000	-13,484,000	-16,460,000	-12,614,000	-10,319,000	-15,398,000	-16,679,000	-14,693,000	-13,885,000	-10,539,000	-10,694,000	-16,757,000	-10,314,000	-10,353,000	-9,941,000	-8,291,000	-8,007,000	-11,959,000	-24,158,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization expense	665,000	644,000	656,000	656,000	685,000	699,000	662,000	543,000	502,000	420,000	309,000	241,000	243,000	239,000	226,000	195,000	184,000	184,000	182,000	180,000	176,000	174,000
stock-based compensation expense	11,040,000	10,359,000	9,609,000	10,247,000	10,199,000	8,838,000	7,545,000	6,339,000	6,161,000	4,978,000	3,984,000	3,686,000	3,409,000	3,533,000	2,273,000	2,006,000	1,654,000	1,293,000	954,000	924,000	837,000	262,000
accretion of discounts on investments	-1,045,000	-1,359,000		-1,918,000
amortization of debt discount and debt issuance costs	58,000	59,000	59,000	59,000	57,000	57,000	58,000	69,000	52,000	39,000	39,000	39,000	39,000	41,000	31,000	12,000	11,000	12,000	12,000	12,000	11,000	11,000
amortization of right-of-use asset	288,000	281,000	275,000	269,000	271,000	281,000	275,000	270,000	254,000	242,000	260,000	254,000	215,000	158,000	155,000	152,000	149,000	146,000	142,000	140,000	138,000	162,000
non-cash interest expense	187,000	222,000	219,000	201,000	181,000	218,000	214,000	349,000				200,000			-8,000	82,000	84,000	83,000	77,000	40,000	84,000	471,000
loss on disposal of property and equipment			16,000	0	0	144,000	5,000	0	55,000	120,000					1,000	0
benefit from doubtful accounts receivable
benefit from excess and obsolete inventories	171,000	175,000	175,000	9,000	13,000	1,000	1,000	8,000	5,000	-8,000	21,000	6,000	26,000	24,000	8,000	4,000	13,000	92,000	40,000	35,000	16,000	27,000
changes in assets and liabilities:
accounts receivable	951,000	-3,630,000	-1,794,000	-279,000	-1,569,000	-1,968,000	-988,000	-1,240,000	-1,906,000	-2,038,000	-863,000	771,000	-641,000	-2,036,000	334,000	-1,628,000	917,000	-60,000	1,334,000	-1,953,000	-1,732,000	110,000
inventories	633,000	-785,000	-7,985,000	-3,009,000	-1,896,000	2,109,000	999,000	-2,685,000	105,000	134,000	-1,819,000	-3,288,000	1,334,000	-1,790,000	-1,429,000	672,000	467,000	-1,871,000	-1,087,000	-347,000	-923,000	-2,339,000
prepaid expenses and other current assets	-9,561,000	2,369,000	-1,635,000	266,000	-495,000	-124,000	607,000	110,000	-2,089,000	847,000	1,242,000	1,213,000	-3,810,000	583,000	815,000	421,000	-1,969,000	983,000	625,000	-255,000	-1,857,000	16,000
other assets	-7,000	115,000	17,000	-129,000	-107,000	-17,000	25,000	-15,000	-32,000	-5,000	-10,000	-33,000	-68,000	-6,000	10,000	83,000	62,000	55,000	-212,000	8,000	1,407,000	-651,000
accounts payable	719,000	-2,937,000	586,000	-258,000	67,000	2,668,000	-698,000	589,000	1,057,000	19,000	-2,463,000	2,137,000	-1,051,000	218,000	563,000	-233,000	-1,012,000	1,274,000	-97,000	757,000	-2,332,000	2,287,000
accrued liabilities	9,524,000	-6,256,000	5,662,000	169,000	3,411,000	-6,388,000	2,612,000	1,876,000	548,000	-3,168,000	3,789,000	1,111,000	1,941,000	-2,423,000	2,200,000	3,871,000	-2,013,000	-3,912,000	2,709,000	1,878,000	325,000	52,000
other liabilities	-403,000	-443,000	-85,000	-319,000	-340,000	-471,000	-346,000	-346,000	-378,000	380,000	-1,176,000	989,000	-328,000	-5,000	-150,000	183,000	196,000	-203,000	-200,000	-197,000	697,000	-1,069,000
net cash from operating activities	-3,383,000	-15,322,000	-8,453,000	-6,798,000	-4,616,000	-12,147,000	-2,724,000	-4,726,000	-10,406,000	-14,725,000	-11,432,000	-6,495,000	-9,036,000	-11,972,000	-14,269,000	-4,423,000	-11,581,000	-11,795,000	-5,261,000	-6,346,000	-9,383,000	-8,620,000
capex	-946,000	-161,000	-457,000	-318,000	-436,000	-229,000	-1,626,000	-318,000	-1,510,000	-1,434,000	-2,912,000	-117,000	-630,000	39,000	-10,000	-90,000	-267,000	-112,000	23,000	-129,000	-15,000	-95,000
free cash flows	-4,329,000	-15,483,000	-8,910,000	-7,116,000	-5,052,000	-12,376,000	-4,350,000	-5,044,000	-11,916,000	-16,159,000	-14,344,000	-6,612,000	-9,666,000	-11,933,000	-14,279,000	-4,513,000	-11,848,000	-11,907,000	-5,238,000	-6,475,000	-9,398,000	-8,715,000
cash flows from investing activities
purchases of property and equipment	-954,000	-388,000	-453,000	-333,000	-434,000	-287,000	-1,567,000	-389,000	-977,000	-2,072,000	-2,752,000	-1,132,000	-807,000	-67,000		-108,000	-345,000	-134,000		-131,000
purchases of investments	-71,595,000	-43,871,000	-26,127,000	-34,711,000	-87,724,000	-26,407,000	-114,484,000	-32,506,000							-21,022,000	-35,278,000	-21,632,000	-1,974,000
proceeds from maturity of investments	62,875,000	62,000,000	25,000,000	42,500,000	69,000,000	32,800,000					17,000,000	9,100,000	15,000,000	36,300,000	34,175,000	28,000,000	7,180,000	2,000,000
net cash from investing activities	-9,674,000	17,741,000	-1,580,000	7,456,000	-19,158,000	6,106,000	-104,951,000	-32,895,000	-22,150,000	-2,072,000	14,250,000	7,968,000	14,193,000	36,233,000	12,898,000	-7,386,000	-14,797,000	-108,000	-69,619,000	-131,000	-89,000	-117,000
cash flows from financing activities
proceeds from issuance of common stock			1,055,000	130,000	1,592,000	1,110,000	2,729,000	1,338,000	1,561,000	168,000	1,739,000	2,242,000	2,117,000	848,000	2,359,000	1,130,000	1,405,000	274,000	1,784,000	68,000	363,000	375,000
net cash from financing activities			1,055,000	130,000	1,592,000	1,110,000	111,727,000	1,213,000	26,591,000	168,000	1,771,000	2,242,000	2,117,000	848,000	8,369,000	835,000	72,268,000	274,000	1,784,000	507,000	112,210,000	-744,000
net change in cash and cash equivalents
cash and cash equivalents, beginning of period
cash and cash equivalents, end of period
supplemental disclosure of cash flow information
cash paid for interest	1,479,000	1,440,000	1,457,000	1,472,000	1,474,000	1,418,000	1,460,000	1,296,000	505,000	582,000	789,000	394,000	595,000	582,000	4,581,000	1,120,000	1,108,000	1,108,000	1,127,000	1,125,000	1,112,000	870,000
noncash investing and financing activities:
accounts payable and accrued liabilities for purchases of property and equipment	8,000	227,000	-4,000	15,000	-2,000	58,000	-59,000	71,000	-533,000	638,000	-160,000	1,015,000	177,000	106,000	-10,000	18,000	78,000	22,000	23,000	2,000	-15,000	22,000
right-of-use asset obtained in exchange for lease obligation			0	0			0	0			-91,000	0							0	0	0	3,982,000
net change in cash, cash equivalents and restricted cash		2,419,000	-8,978,000	788,000	-22,182,000	-4,931,000	4,052,000	-36,408,000	-5,965,000	-16,629,000	4,589,000	3,715,000	7,274,000	25,109,000	6,998,000	-10,974,000	45,890,000	-11,629,000	-73,096,000	-5,970,000	102,738,000	-9,481,000
cash, cash equivalents and restricted cash, beginning of period		20,210,000		0	0	55,513,000		0	0	110,463,000		0	0	69,776,000		0	0	39,491,000		0	0	25,300,000
cash, cash equivalents and restricted cash, end of period		22,629,000		788,000	-22,182,000	50,582,000		-36,408,000	-5,965,000	93,834,000		3,715,000	7,274,000	94,885,000		-10,974,000	45,890,000	27,862,000		-5,970,000	102,738,000	15,819,000
amortization of premiums (accretion of discounts) on investments						-1,753,000	-1,081,000	-274,000							159,000	88,000
loss on extinguishment of debt							0	0
benefit from (recovery of) doubtful accounts receivable
changes in operating assets and liabilities:
proceeds from sale of property and equipment
proceeds from public offerings, net of underwriting discount, commissions and offering costs paid															0	-295,000
proceeds from long-term debt							-1,089,000	0
principal repayment of long-term debt
proceeds from disgorgement of short-swing profits
cash, cash equivalents and restricted cash, beginning of year
cash, cash equivalents and restricted cash, end of year
change in accounts receivable allowances				26,000	0	19,000
principal repayment of debt								0
payments of debt issuance costs								-116,000
payments of deferred offering costs																						-1,149,000
unpaid debt issuance costs								-116,000
unpaid deferred offering costs																						1,204,000
change in benefit from doubtful accounts receivable							0	0	3,000	-6,000					-6,000	-17,000	0	-9,000
repayment of interest paid in kind
payments of prepayment penalty and lender fees
amortization of premiums on investments												64,000	201,000	186,000
change in fair value of redeemable convertible preferred stock warrant liability																			0	0	5,318,000	15,712,000
proceeds from exercise of redeemable convertible preferred stock warrants																			0	0
proceeds from exercise of common stock warrants																			0	0
net exercise of convertible preferred stock warrants to preferred stock																				0
conversion of convertible preferred stock to common stock upon initial public offering																				0
offering costs in accrued liabilities
changes in assets and liabilities
purchase of property and equipment																						-117,000
non-controlling interest
non-cash investing and financing activities:
landlord paid tenant improvements
net exercise of redeemable convertible preferred stock warrants to preferred stock
conversion of redeemable convertible preferred stock to common stock upon initial public offering
offering costs in accounts payable and accrued liabilities																-295,000
amortization of premium on investments																		79,000
payment of deferred offering costs
accretion of discount on investments
proceeds from initial public offering, net of underwriting discount, commissions and offering costs paid																			0	439,000
benefit from sales returns and allowances
benefit from accounts receivable allowances																					411,000	313,000
proceeds from exercise of preferred stock warrants																						30,000

We provide you with 20 years of cash flow statements for Silk Road Medical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Silk Road Medical stock. Explore the full financial landscape of Silk Road Medical stock with our expertly curated income statements.

The information provided in this report about Silk Road Medical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.